Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Paine

Showing results (161-170 of 175) with videos related to

Pageof 18
Sort By:
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 10, 2023
Goldenseal-Mediated Inhibition of Intestinal Uptake Transporters Decreases Metformin Systemic Exposure in MiceVictoria O Oyanna, Kenisha Y Garcia-Torres, Baron J Bechtold, et al.
Pharmaceutics|March 26, 2022
Clinical Pharmacokinetic Assessment of Kratom (<i>Mitragyna speciosa</i>), a Botanical Product with Opioid-like Effects, in Healthy Adult ParticipantsRakshit S Tanna, James T Nguyen, Deena L Hadi, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 15, 2015
Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction study designCaroline A Lee, Meeghan A O'Connor, Tasha K Ritchie, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 24, 2007
The influence of CYP3A5 expression on the extent of hepatic CYP3A inhibition is substrate-dependent: an in vitro-in vivo evaluationNina Isoherranen, Shana R Ludington, Raymond C Givens, et al.
Scientific Reports|November 6, 2020
Chemical composition and biological effects of kratom (Mitragyna speciosa): In vitro studies with implications for efficacy and drug interactionsD A Todd, J J Kellogg, E D Wallace, et al.
Plos Neglected Tropical Diseases|February 6, 2015
Chemotherapy of second stage human African trypanosomiasis: comparison between the parenteral diamidine DB829 and its oral prodrug DB868 in vervet monkeysJohn K Thuita, Kristina K Wolf, Grace A Murilla, et al.
Clinical and Translational Science|August 28, 2023
Co-consuming green tea with raloxifene decreases raloxifene systemic exposure in healthy adult participantsJohn D Clarke, Sabrina M Judson, Dan-Dan Tian, et al.
Current Opinion in Investigational Drugs (London, England : 2000)|August 20, 2010
Diamidines for human African trypanosomiasisMary F Paine, Michael Zhuo Wang, Claudia N Generaux, et al.
Pharmaceutical Biology|November 19, 2025
An exploratory evaluation of the interaction risk between herbal products and pharmaceutical medicines used concurrently for disease management in Blantyre, MalawiKumbukani K Nyirenda, John Mponda, Ibrahim Chikowe, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 26, 2006
CYP4F enzymes are the major enzymes in human liver microsomes that catalyze the O-demethylation of the antiparasitic prodrug DB289 [2,5-bis(4-amidinophenyl)furan-bis-O-methylamidoxime]Michael Zhuo Wang, Janelle Y Saulter, Etsuko Usuki, et al.
Pageof 18

Showing results (161-170 of 175) with videos related to

Sort By:
Pageof 18
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 10, 2023
Goldenseal-Mediated Inhibition of Intestinal Uptake Transporters Decreases Metformin Systemic Exposure in MiceVictoria O Oyanna, Kenisha Y Garcia-Torres, Baron J Bechtold, et al.
Pharmaceutics|March 26, 2022
Clinical Pharmacokinetic Assessment of Kratom (<i>Mitragyna speciosa</i>), a Botanical Product with Opioid-like Effects, in Healthy Adult ParticipantsRakshit S Tanna, James T Nguyen, Deena L Hadi, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 15, 2015
Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction study designCaroline A Lee, Meeghan A O'Connor, Tasha K Ritchie, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 24, 2007
The influence of CYP3A5 expression on the extent of hepatic CYP3A inhibition is substrate-dependent: an in vitro-in vivo evaluationNina Isoherranen, Shana R Ludington, Raymond C Givens, et al.
Scientific Reports|November 6, 2020
Chemical composition and biological effects of kratom (Mitragyna speciosa): In vitro studies with implications for efficacy and drug interactionsD A Todd, J J Kellogg, E D Wallace, et al.
Plos Neglected Tropical Diseases|February 6, 2015
Chemotherapy of second stage human African trypanosomiasis: comparison between the parenteral diamidine DB829 and its oral prodrug DB868 in vervet monkeysJohn K Thuita, Kristina K Wolf, Grace A Murilla, et al.
Clinical and Translational Science|August 28, 2023
Co-consuming green tea with raloxifene decreases raloxifene systemic exposure in healthy adult participantsJohn D Clarke, Sabrina M Judson, Dan-Dan Tian, et al.
Current Opinion in Investigational Drugs (London, England : 2000)|August 20, 2010
Diamidines for human African trypanosomiasisMary F Paine, Michael Zhuo Wang, Claudia N Generaux, et al.
Pharmaceutical Biology|November 19, 2025
An exploratory evaluation of the interaction risk between herbal products and pharmaceutical medicines used concurrently for disease management in Blantyre, MalawiKumbukani K Nyirenda, John Mponda, Ibrahim Chikowe, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 26, 2006
CYP4F enzymes are the major enzymes in human liver microsomes that catalyze the O-demethylation of the antiparasitic prodrug DB289 [2,5-bis(4-amidinophenyl)furan-bis-O-methylamidoxime]Michael Zhuo Wang, Janelle Y Saulter, Etsuko Usuki, et al.
Pageof 18